Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. filings document the regulatory record for a Nasdaq-listed diagnostics company focused on cell-free DNA and precision medicine. Recent Form 8-K reports furnish results of operations and financial condition, press releases, investor presentations and exhibit information tied to quarterly and annual reporting.
The company’s proxy materials describe board composition, director elections, committee assignments, executive compensation, equity-award disclosures and stockholder voting matters. Its filings also identify the registered common stock class, Nasdaq Global Select Market listing, governance actions and other material-event disclosures relevant to Natera’s public-company reporting.
Natera, Inc. executive John Fesko, its President and Chief Business Officer, reported two sales of Natera common stock on February 3, 2026. He sold 1,179 shares at $230.768 and 2,415 shares at $231.14, both reported as direct holdings.
According to the filing, each sale was made to satisfy tax withholding and remittance obligations from vesting restricted stock units and was executed under written instructions intended to meet Rule 10b5-1(c) affirmative defense conditions. After these transactions, Fesko directly beneficially owns 178,081 shares of Natera common stock.
Natera, Inc. director and co-founder Sheena Jonathan reported a small sale of company stock. On February 3, 2026, she sold 435 shares of Natera common stock at $230.768 per share. The sale was made to cover tax withholding and remittance obligations tied to the vesting of restricted stock units and was executed under a written instruction intended to meet Rule 10b5-1(c) affirmative defense conditions in her January 31, 2025 stock unit agreement.
After this transaction, Jonathan directly holds 263,161 shares of Natera common stock. In addition, 21,782 shares are held by Caraluna 1 Trust and 21,782 shares are held by Caraluna 2 Trust for the benefit of trust beneficiaries, and she disclaims beneficial ownership of those trust-held shares.
Natera, Inc. officer Daniel Rabinowitz, the company’s Secretary and Chief Legal Officer, reported selling 1,334 shares of Natera common stock on February 3, 2026 at a price of $230.768 per share. After this transaction, he beneficially owned 223,813 shares directly.
The filing explains that the sale was carried out to cover tax withholding and remittance obligations arising from the vesting of restricted stock units (RSUs). It was executed under a written instruction intended to meet the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act, indicating it was a pre-arranged, rule-compliant sale plan linked to prior equity grants.
Natera, Inc. reported that its President and Chief Business Officer, John Fesko, received an award of 6,135 restricted stock units (RSUs) of Natera common stock on January 30, 2026. These RSUs vested immediately upon issuance, and each RSU represents one share of common stock.
Following this equity grant, Fesko directly beneficially owns 181,675 shares of Natera common stock. The transaction was recorded at a price of $0.00 per share, reflecting a compensatory stock award rather than an open-market purchase.
Natera, Inc. director received 73 shares of common stock on January 30, 2026 through an award of restricted stock units (RSUs) granted in lieu of a $17,500 quarterly cash retainer for Board service.
The RSUs were fully vested at issuance, and each RSU converts into one share of Natera common stock. Following this grant, the director directly holds 5,389 shares of Natera common stock.
Natera, Inc. director Herm Rosenman reported a stock-based board fee. On 01/30/2026 he received 99 shares of Natera common stock through fully vested Restricted Stock Units granted in lieu of a quarterly board retainer of $23,750.
Each RSU represents one share of Natera common stock, so the grant directly increased his holdings. After this transaction, Rosenman beneficially owned 20,441 shares of Natera common stock held directly.
Natera, Inc. director Marcus Gail Boxer received an award of 91 restricted stock units on 01/30/2026 as part of his Board compensation. The RSUs were issued in lieu of quarterly retainer fees of $21,875 and were fully vested at issuance.
Each RSU represents a right to receive one share of Natera common stock. Following this grant, Boxer beneficially owned 5,853 shares of Natera common stock in direct ownership.
Natera director Rowan E. Chapman received equity compensation for board service. On 01/30/2026, Chapman was awarded 97 restricted stock units (RSUs) in lieu of a quarterly cash retainer of $23,125 for serving on Natera’s Board of Directors. The RSUs were fully vested at issuance, and each RSU represents one share of Natera common stock. Following this grant, Chapman directly beneficially owned 5,874 shares of Natera common stock.
Natera, Inc. director Roelof Botha received equity compensation for board service. On January 30, 2026, he was issued 112 Restricted Stock Units (RSUs) in lieu of a quarterly cash retainer of $26,875 for serving on Natera's Board of Directors. The RSUs were fully vested at issuance, and each RSU represents a right to receive one share of Natera common stock. Following this grant, Botha directly beneficially owned 2,540 shares of Natera common stock and indirectly beneficially owned 1,154,198 shares through estate planning vehicles.
Natera director Monica Bertagnolli received equity compensation instead of cash fees. On 01/30/2026 she was issued 70 Restricted Stock Units (RSUs) in lieu of a quarterly board retainer of $16,875. The RSUs were fully vested at issuance and each RSU equals one share of Natera common stock, bringing her directly held beneficial ownership to 5,291 shares.